Syndax Pharmaceuticals Inc
$ 24.23
1.76%
17 Apr - close price
- Market Cap 2,100,056,000 USD
- Current Price $ 24.23
- High / Low $ 24.58 / 23.50
- Stock P/E N/A
- Book Value 0.74
- EPS -3.29
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -1.62 %
- 52 Week High 25.59
- 52 Week Low 8.58
About
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$39.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-09 | 2025-11-03 | 2025-08-04 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-01 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-05-08 |
| Reported EPS | -0.78 | -0.7 | -0.83 | -0.9846 | -1.1 | -0.98 | -0.8 | -0.85 | -1 | -0.73 | -0.64 | -0.59 |
| Estimated EPS | -0.5854 | -0.73 | -1.01 | -1.2734 | -0.2289 | -1.11 | -0.91 | -0.98 | -0.99 | -0.8 | -0.73 | -0.6 |
| Surprise | -0.1946 | 0.03 | 0.18 | 0.2888 | -0.8711 | 0.13 | 0.11 | 0.13 | -0.01 | 0.07 | 0.09 | 0.01 |
| Surprise Percentage | -33.2422% | 4.1096% | 17.8218% | 22.6794% | -380.5592% | 11.7117% | 12.0879% | 13.2653% | -1.0101% | 8.75% | 12.3288% | 1.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNDX
2026-04-17 06:10:14
Syndax Pharmaceuticals (NASDAQ:SNDX) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average one-year price target of $40.33. Recent insider selling by the CEO and CFO totaled over $432,000, reducing their stakes. Despite a significant 792.6% year-over-year revenue jump to $68.7 million in the latest quarter, the company missed EPS estimates at ($0.78) versus ($0.64) expected, remaining unprofitable with a market cap around $2.1 billion.
2026-04-14 21:39:30
Syndax Pharmaceuticals (SNDX) has seen a 116% surge over the past year, prompting an analysis of its valuation. A Discounted Cash Flow (DCF) model suggests the stock is undervalued by 71.3% at US$24.25 per share, indicating a potential intrinsic value of US$84.40. However, using a Price-to-Sales (P/S) ratio, Syndax Pharmaceuticals appears overvalued with a P/S of 12.41x compared to its calculated "Fair Ratio" of 1.78x.
2026-04-12 16:10:00
This article provides a liquidity mapping analysis for Syndax Pharmaceuticals Inc. (SNDX), highlighting a neutral near and mid-term outlook that could moderate a long-term positive bias. It details an exceptional 42.0:1 risk-reward setup targeting a 12.5% gain versus 0.3% risk, along with AI-generated trading strategies for various risk profiles. The analysis includes specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies.
2026-04-11 11:09:09
This article provides a comprehensive overview of Syndax Pharmaceuticals (SNDX) SEC filings, including 10-K, 10-Q, and 8-K forms, accessible through Stock Titan. It highlights recent filings such as a Rule 144 Notice for share sales, Goldman Sachs Group's ownership stake, insider trading activity by the CFO, and a director's resignation. The platform offers AI-powered summaries and sentiment analysis for these regulatory documents, which are crucial for investors to understand the company's financial results, material events, and regulatory milestones.
2026-04-08 19:10:00
Syndax Pharmaceuticals (NASDAQ:SNDX) reached a new 52-week high of $25.70, driven by growing investor confidence in its advanced cancer treatment pipeline. The stock's performance reflects positive data from clinical trials of its lead candidate, entinostat, an HDAC inhibitor. While the milestone is positive, analysts are divided on whether its current valuation presents a buying opportunity.
2026-04-08 14:40:21
Syndax Pharmaceuticals' stock reached a new 52-week high of $25.70, indicating growing investor confidence in its cancer treatment pipeline, especially its lead candidate entinostat. While the performance is positive, analysts are divided on whether the current valuation presents a buying opportunity, suggesting that further data and regulatory milestones are crucial for long-term prospects. The company, based in Waltham, Massachusetts, develops novel therapies for various solid tumor and hematologic indications.
